Načítá se...
PARP inhibitors for Homologous Recombination- Deficient Prostate Cancer
INTRODUCTION: Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant di...
Uloženo v:
| Vydáno v: | Expert Opin Emerg Drugs |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088797/ https://ncbi.nlm.nih.gov/pubmed/29595348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2018.1459563 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|